Oscity BioSciences Acquires Enantia's Cannabinoid Cocrystal Technology Patents
News related to:Oscity BioSciences · 2 min read
FOLEY, AL, UNITED STATES, September 30, 2026 /CourierPR/ -- Oscity BioSciences, a vertically integrated company specializing in advanced cannabinoid technologies, has acquired foundational U.S. patents covering cannabinoid cocrystal technology from Enantia, S.L.U., a leading international solid-state chemistry and process development firm based in Barcelona. The acquisition aims to expand Oscity's production capabilities and enhance its research and development efforts in the pharmaceutical application of cannabinoids.
The patents, U.S. Patent Nos. 11,168,047 and 11,993,563, cover novel cocrystals of cannabinoids, including cannabidiol, with selected coformers. These patents also encompass processes for their preparation and purification, as well as solid compositions thereof. The acquisition is expected to enable Oscity to produce highly efficient and pure cannabinoid forms without traditional chromatography, while delivering improved physicochemical properties such as enhanced stability, higher melting points, greater consistency, and potentially superior solubility and bioavailability.
Enantia, known for its expertise in pharmaceutical solid-state research, has been a pioneer in the field for over two decades.
The acquisition underscores Oscity BioSciences' strategy of combining proprietary process innovation with high-quality intellectual property to address longstanding challenges in cannabinoid purification, formulation, and drug development. The company intends to explore applications ranging from high-purity API production to potential clinical-stage medication candidates with pharmaceutical industry partners.
Oscity BioSciences operates from a cGMP-certified facility in Foley, Alabama, and is focused on pioneering patented cannabinoid technologies. The company's commitment to developing proprietary extraction, refinement, and cocrystal processes aims to produce high-purity cannabinoid ingredients and support pharmaceutical and wellness applications.
The acquired intellectual property includes U.S. Patent Nos. 11,168,047 and 11,993,563, which cover novel cocrystals of cannabinoids (including cannabidiol) with selected coformers, processes for their preparation and purification, and solid compositions thereof. These patented technologies enable highly efficient purification of cannabinoids without traditional chromatography, while delivering improved physicochemical properties such as enhanced stability, higher melting points, greater consistency, and potentially superior solubility and bioavailability, attributes critical for pharmaceutical-grade active pharmaceutical ingredients (APIs).
Under the collaboration, Oscity and Enantia will jointly pursue further research and development of cannabinoid cocrystals aimed at enabling next-generation pharmaceutical-grade solid forms and API candidates. Integration of this process into current workflow leverages Oscity’s cGMP-certified manufacturing capabilities in Foley, Alabama, and Enantia’s expertise in solid-form screening, process chemistry, and crystalline engineering.
The acquisition underscores Oscity BioSciences' strategy of combining proprietary process innovation with high-quality intellectual property to address longstanding challenges in cannabinoid purification, formulation, and drug development. Oscity BioSciences intends to explore applications ranging from high-purity API production to potential clinical-stage medication candidates with pharmaceutical industry partners.